HC Wainwright & Co. Maintains Buy on Autolus Therapeutics, Raises Price Target to $10

AUTOLUS THERAPEUTICS LTD

AUTOLUS THERAPEUTICS LTD

AUTL

0.00

HC Wainwright & Co. analyst Emily Bodnar maintains Autolus Therapeutics (NASDAQ: AUTL) with a Buy and raises the price target from $9 to $10.